6:07 PM
 | 
Nov 06, 2008
 |  BC Extra  |  Clinical News

Aegerion's AEGR-733 meets Phase II endpoints

Aegerion (Bridgewater, N.J.) said its AEGR-733 met the primary...

Read the full 34 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >